Cytonus’ tech helps oncolytic viruses evade immune system

By Ben Hargreaves contact

- Last updated on GMT

Cytonus to speak on potential of Cargocytes at BIO

Related tags: Cytonus, Cargocytes, Immunotherapy, Oncolytic viruses

Cytonus will present at BIO regarding the development of Cargocytes, which offer a delivery system for immunotherapy treatments.

Cytonus Therapeutics, a San Diego-based biotech, is putting its Cargocyte technology platform through pre-clinical studies for the delivery of oncolytic viruses, but also has the potential to be used in gene therapy, therapeutic RNAs, small molecule compounds, and other immune-modulating treatments.

The US company will present its platform at BIO International Convention, whilst also discussing its corporate strategy and developments plans, Cytonus’ CEO, Remo Moomiaie-Qajar, told us.

Moomiaie-Qajar explained that the aim for attending the conference is to “educate our peers in the industry about the attributes and benefits of using our Cargocytes to deliver therapeutics to tissue in a safer, more precise way.”

“We hope that the versatility of our platform sparks the interest of potential collaborators who have unique therapeutics that need a delivery vehicle,”​ he continued.

The biotech will present its preclinical data to attendees, which studied the use of Cargocyte delivery technology alongside oncolytic viruses to treat triple negative breast cancer.

According the company, the data showed that 40% of animals treated showed no sign of disease more than 260 days post-treatment, while control animals typically died within 25 to 30 days.

Moomiaie-Qajar outlined why this benefit is seen, “With our delivery vehicle, the oncolytic virus is able to evade the immune system and home specifically to tumour cells, where they infect the tumour cells and destroy them.”

This avoids the issue whereby the immune system acts to destroy the viruses, which current delivery methods have experienced issues with, Moomiaie-Qajar added.

As well this, Cargocytes are able to carry multiple different therapeutics and actively migrate out of the vasculature.

The work Cytonus is carrying out taps into a growing interest in utilising oncolytic viruses therapeutically, which is seeing manufacturers expand capacity​ to meet demand and increased investment​ in the area, on the part of big pharma companies.

Related news

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers